PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
Ann Oncol. 2019 Jul 1;30(7):1180.
doi: 10.1093/annonc/mdy536.